In:
Current Medicinal Chemistry, Bentham Science Publishers Ltd., Vol. 30, No. 37 ( 2023-11), p. 4266-4276
Abstract:
NR2F1-AS1 is a long non-coding RNA (lnc RNA) that is involved in different biological processes. It plays an integral role in the pathophysiology
of human diseases, especially tumorigenesis and progression. Therefore, it may be a promising target for numerous tumor biotherapeutics. The current review study aimed to
show the pathophysiological activities and processes of RNA NR2F1-AS1 in cancer cells. Methods: The contents of the present review were based on information obtained from
PubMed. In the data search, “NR2F1-AS1” was chosen as the first keyword, whereas “cancer” was chosen as the second keyword. This review selected and summarized
studies published between 2019-2021, concerning the biological functions and mechanisms of NR2F1-AS1 in the development of tumorigenesis. Results: It was found that NR2F1-AS1 regulates a variety of biological activities such as
proliferation, invasion, migration, and apoptosis. It acts as an oncogene because it is abnormally expressed and promotes the progression of cancer in a variety of malignancies,
including esophageal squamous cell carcinoma, non-small cell lung cancer, breast cancer, neuroblastoma, endometrial cancer, thyroid cancer, and gastric cancer. However, it
was evident that NR2F1-AS1 inhibits the progression of cancer in cervical squamous cell carcinoma. Conclusion: NR2F1-AS1 is a potential new biomarker and therapeutic target for the treatment
of different cancers.
Type of Medium:
Online Resource
ISSN:
0929-8673
DOI:
10.2174/0929867330666230112165503
Language:
English
Publisher:
Bentham Science Publishers Ltd.
Publication Date:
2023
SSG:
15,3
Permalink